| Date |
Subject |
Media |
| 2025-09-10 |
Genomics BioSci & Tech. Chairman Michael Chou Rallies Partners to Drive AI-Powered Drug Development
|
The global boom in AI applications is reshaping the biotechnology and healthcare industries, with AI increasingly being used to accelerate drug discovery and development. This shift has fueled a wave of new strategic alliances. Genomics BioSci & Tech. (Genomics) entered the U.S. market in 2023 through its investment in Wyzer, and in 2024, it raised capital for its subsidiary LAI SHI TE SHENG YI, bringing in strategic investors to speed up new drug development. In July this year, Chairman Michael Chou (周孟賢) personally attended a forum announcing a strategic alliance with BIONET Corp., highlighting his determination to accelerate Genomics’ diversification and global expansion. |
| 2025-09-10 |
Core Business and Non-Operating Gains Boost CHLITINA HOLDING LIMITED’s Q2 EPS to NT$2.62, Up 285% Quarter-on-Quarter
|
CHLITINA HOLDING LIMITED (CHLITINA-KY) reported that thanks to growth in its core business and non-operating financial subsidies totaling RMB 18 million, its Q2 operating profit reached NT$147 million, up 54% quarter-on-quarter. Net profit attributable to the parent company was NT$216 million, representing a 285% quarterly increase, with earnings per share (EPS) of NT$2.62. For the first half of the year, net profit attributable to the parent company totaled NT$272 million, with an EPS of NT$3.3. |
| 2025-09-10 |
TCI’s Asset-Light Expansion Moves into Spain: New Equipment in Place, Tariff Impact Eases, H2 Performance Set to Strengthen
|
Vincent Lin, Chairman of TCI, stated yesterday (21st) that the company has successfully entered the top three global pharmaceutical companies, the top three U.S. direct selling companies, and major international internet giants, marking its transformation into a truly global enterprise operating simultaneously across the U.S., Europe, and Asia-Pacific. To support this expansion, TCI is advancing its “asset-light strategy” and is currently evaluating the establishment of a production base in Spain. |
| 2025-09-10 |
Orient Pharma Expands International Footprint with ADHD Drug Push
|
OEP Group’s biotech subsidiary Orient Pharma was listed on the Taipei Exchange on the 21st. Chairman Tsai, Cheng-Hung stated that the company will continue to capitalize on patent expirations and market gaps, leveraging its core technology platforms to build a differentiated product portfolio and enhance global competitiveness. |
| 2025-09-10 |
MAXIGEN BIOTECH Launches U.S. Investment, Targeting Opportunities in Healthy Ageing and Regenerative Medicine
|
MAXIGEN BIOTECH is accelerating its global transformation from a manufacturer to a branded company. General Manager Ching-Ting Chen stated that the company aims to increase its brand-driven revenue contribution from the current 60% to 80% by 2030. This year, it will establish a U.S. subsidiary for business operations, with medium- to long-term manufacturing also planned to move to the United States. |
| 2025-09-10 |
TTY Biopharm’s Three-Pronged Growth Strategy Continues; Second-Half Revenue Expected to Surpass First Half
|
TTY Biopharm posted record-high revenue and operating profit in the first half of 2025, with EPS at NT$2.72. At the company’s investor conference on the 20th, General Manager Sara Hou said TTY’s “three-pronged strategy” continues to advance. Its complex generic drug Lipo-AB is achieving new sales highs in the U.S., shipments of its cell-based influenza vaccine are expected to rise further, and its breast cancer hormone therapy obtained a new second-line combination CDK4/6 indication this July. The company also expects Taiwan’s first domestically developed lung cancer drug to receive approval in the fourth quarter. Over the next three years, three additional products are slated for launch. Analysts expect second-half revenue to exceed the first half, with full-year revenue growth in the high single-digit to double-digit range. |
| 2025-09-10 |
FORMOSA BIOMEDICAL TECHNOLOGY Partners with UWELL Biopharma to Build Next-Generation CAR-T Commercial Production Model
|
Formosa Biomedical Technology, a subsidiary of Formosa Plastics Group, has been diversifying its business in recent years. On the 20th, it jointly announced with UWELL Biopharma a collaboration to advance the clinical development and commercialization of next-generation CAR-T cell therapy. UWELL’s anti-CD19 CAR-T therapy candidate, UWC19, is scheduled to begin a multicenter Phase II clinical trial in the fourth quarter of this year. Formosa Biomedical Technology will leverage its strengths in drug formulation and production to support the effort, aiming to bring Taiwan’s advanced cell therapy industry onto the global stage. |
| 2025-09-10 |
Inventec Appliances Deploys Thousands of Infusion Pumps at Chi-Mei Hospital to Enhance Care Efficiency
|
Inventec Appliances, a subsidiary of the Inventec Group, announced that its SmartMed Infusion System has been officially deployed at Chi-Mei Hospital, making it the first hospital in southern Taiwan to adopt this smart infusion solution. This initiative reflects Chi-Mei Hospital’s proactive approach to smart healthcare development and underscores its strong commitment to clinical medication safety and patient care quality. |
| 2025-09-10 |
Climate Crisis Is a Health Crisis! Chih-Hung Chen: Medical Resilience Cannot Wait
|
The impact of climate disasters on Taiwan is intensifying. Since July, the island has been battered by three consecutive typhoons—Danas, Vipa, and Yangliu—with the coastal regions of Chiayi and Tainan suffering severe agricultural losses and infrastructure damage due to heavy rainfall. Experts warn that this is not only an environmental challenge but also a serious public health crisis. |
| 2025-09-08 |
Polaris Group-KY’s New Drug for Malignant Pleural Mesothelioma Enters FDA Substantive Review; U.S. Distribution Licensing to Accelerate
|
Polaris Group-KY announced that its new drug Pegargiminase (ADI-PEG 20), developed for the treatment of malignant pleural mesothelioma, has officially entered the substantive review stage with the U.S. FDA. This news drove the company’s stock to surge to its daily limit immediately after opening. If the FDA review and the planned U.S. inspection next February proceed smoothly, the drug could receive approval as early as the first half of next year, while discussions on U.S. market distribution licensing are expected to accelerate, potentially being finalized in Q1 2026. |
